Tag Archives: NervGen Pharma Corp

NervGen looking to use their technology to revolutionize nerve damage treatment

Posted on April 12, 2019 by

NervGen Pharma (CVE:NGEN) President and CEO Ernest Wong sat down with Steve Darling from Proactive Investors Vancouver to talk about the pharma company that has technology that hopes to regenerate nerve damage, that damage can be spinal cord or peripheral. … Continue reading →

Posted in Regenerative Medicine, spinal cord injury research, Uncategorized | Tagged , ,

NERVGEN PHARMA COMPLETES $10 MILLION INITIAL PUBLIC OFFERING

Posted on March 13, 2019 by

Vancouver, Canada. March 13, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering (“IPO”) of … Continue reading →

Posted in Ligand, Regenerative Medicine, spinal cord injury research | Tagged , ,

Dr Jerry Silver – Spinal Cord Damage and Emerging Treatments

Posted on February 17, 2019 by

“Injuries to the spinal cord can cause permanent paralysis and even lead to death, with little to no hope of regaining lost functions once the trauma has occurred. Dr Jerry Silver and his team at Case Western Reserve University Medical … Continue reading →

Posted in Chronic Spinal Cord Injury Research, Ligand, Regenerative Medicine, spinal cord injury research | Tagged , ,

Worldwide licensing agreement made on peptide developed in Silver laboratory at Case Western Reserve University

Posted on July 18, 2018 by

Read the Full Article at Globe Newswire.   VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and … Continue reading →

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research | Tagged , , ,